Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $51.54 USD
Change Today -0.02 / -0.04%
Volume 1.5M
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

isis pharmaceuticals inc (ISIS) Key Developments

Isis Pharmaceuticals, Inc. Revised Earnings Guidance for the Full Year 2015

Isis Pharmaceuticals, Inc. revised earnings guidance for the full year 2015. Because of strong financial performance in the first half of 2015, the company expects to substantially improve upon year-end guidance. The company is reducing projected pro forma NOL by more than 40% to a pro forma NOL in the low $30 million range. The company also projecting to end the year with more than $750 million in cash, which is an increase over original cash guidance of more than $120 million and a modest increase over 2014 year end cash balance. The revised guidance also reflects the many opportunities have to generate revenue and cash throughout the second half of 2015.

Isis Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Isis Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, revenue was $120.4 million compared to $57.1 million for the same period in 2014. Net income of $35.6 million compared to a net loss of $12.1 million for the same periods in 2014. Diluted net income per share was $0.29 compared to a diluted net loss of $0.10 for the same period in 2014. Income from operations was $44,646,000 against loss from operations of $6,650,000 a year ago. For the six months, revenue was $183.0 million compared to $85.2 million for the same period in 2014. Net income of $18.9 million compared to a net loss of $43.4 million for the same period in 2014. Diluted net income per share $0.15, compared to a diluted net loss of $0.37 for the same period a year ago. Income from operations was $35,317,000 against loss from operations of $36,317,000 a year ago.

Isis Reports Positive Data from KYNAMRO® (mipomersen sodium) FOCUS FH Phase 3 Study in Patients with Severe Heterozygous Familial Hypercholesterolemia

Isis Pharmaceuticals Inc. announced that the FOCUS FH phase 3 study of KYNAMRO® (mipomersen sodium) in patients with severe heterozygous familial hypercholesterolemia (severe HeFH) met its primary efficacy endpoint, a statistically significant reduction in LDL-cholesterol after 60 weeks of treatment of once weekly injections of 200 mg of KYNAMRO compared to placebo. LDL-cholesterol reduction was similar to that observed in previous phase 3 studies. In addition, based on the data available for review, the safety profile of KYNAMRO observed in the FOCUS FH trial was similar to the safety profile reported in previous phase 3 studies. Genzyme will provide a more in depth review of the safety and efficacy data at a future medical meeting.

AstraZeneca and Isis Pharmaceuticals, Inc. to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases

Isis Pharmaceuticals, Inc. and AstraZeneca announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration builds on a broad existing relationship between the two companies and supports AstraZeneca's strategic approach in these therapeutic areas using novel RNA-targeted treatments. It also enables Isis Pharmaceuticals to extend use of its antisense technology to diseases of the kidney. Antisense drugs are short, chemically modified, single-stranded nucleic acids (antisense oligonucleotides) that have the ability to target any gene product of interest. They offer new opportunities for therapeutic intervention because they act inside the cell to influence protein production by targeting RNA to either prevent the production of disease-causing proteins, increase the production of proteins deficient in disease, or target toxic RNAs that are unable to generate proteins. AstraZeneca will pay an upfront fee of $65 million to Isis Pharmaceuticals plus development and regulatory milestones for each program that AstraZeneca advances to clinical development. Isis Pharmaceuticals is also eligible to earn tiered double-digit royalties on annual net sales for each program. This transaction is subject to clearances under the Hart-Scott Rodino Antitrust Improvements Act.

Isis Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 04, 2015

Isis Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISIS:US $51.54 USD -0.02

ISIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $38.17 USD +0.26
Acorda Therapeutics Inc $32.73 USD +1.04
Alnylam Pharmaceuticals Inc $109.07 USD +4.17
Depomed Inc $28.38 USD -0.42
Impax Laboratories Inc $42.40 USD -1.57
View Industry Companies
 

Industry Analysis

ISIS

Industry Average

Valuation ISIS Industry Range
Price/Earnings 100.0x
Price/Sales 19.8x
Price/Book 20.6x
Price/Cash Flow 265.3x
TEV/Sales 15.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.